--Aspen Technology Board Authorizes Buy Back Up to $100 Million of Shares in Fiscal 2025-March 2024-www.financetom.com

--Aspen Technology Board Authorizes Buy Back Up to $100 Million of Shares in Fiscal 2025

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

--Aspen Technology Board Authorizes Buy Back Up to $100 Million of Shares in Fiscal 2025

Aug 6, 2024 2:05 PM

04:51 PM EDT, 08/06/2024 (MT Newswires) --

Price: 195.36, Change: +17.52, Percent Change: +9.85

Previous page： --Gritstone bio Slumps Premarket After Disclosing 19% Reduction in Workforce Next page： Market Chatter: Meta Platforms Implements Job Cuts Across Instagram, WhatsApp, Reality Labs

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

--Gritstone bio Slumps Premarket After Disclosing 19% Reduction in Workforce

Oct 17, 2024

05:26 AM EDT, 10/17/2024 (MT Newswires) -- Price: 0.0549, Change: -0.01, Percent Change: -17.00 ...

Market Chatter: Meta Platforms Implements Job Cuts Across Instagram, WhatsApp, Reality Labs

Oct 17, 2024

04:33 AM EDT, 10/17/2024 (MT Newswires) -- Meta Platforms ( META ) is laying off employees across several divisions, including Instagram, WhatsApp and Reality Labs, The Verge reported Wednesday, citing people familiar with the matter. The company is moving some teams to different locations and reallocating employees, with efforts made to find new opportunities for those affected, a Meta spokesperson...

BRIEF-Eni's sale of biofuel unit stake to KKR expected by year-end, CEO says

Oct 17, 2024

Oct 17 (Reuters) - Eni Chief Executive Claudio Descalzi tells reporters on the sidelines of an event in Milan : * WILL CLOSE BY YEAR END SALE OF STAKE IN ENILIVE TO KKR * FALL IN OIL PRICES IMPACTING MARGINS, BUT LESS THAN IN THE PAST THANKS TO DIVERSIFICATION Further company coverage: (Reporting by Milan newsroom) ...

Verastem Reports Updated Data on Phase 2 Study of Ovarian Cancer Combination Therapy

Oct 17, 2024

05:18 AM EDT, 10/17/2024 (MT Newswires) -- Verastem Oncology (VSTM) said Thursday that updated data from a phase 2 study evaluating the combination of avutometinib and defactinib in patients with recurrent low-grade serous ovarian cancer demonstrated robust overall response rates. The company said all evaluable patients with measurable disease showed a confirmed overall response rate of 31%, with about 12...